Американское общество гирудотерапии

Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process

Research article published in Journal of vascular research (1994)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Разработка лекарственных препаратовWalters TK et al. · Journal of vascular research, 1994

Abstract

Vascular injury, activation of the coagulation system and thrombosis are common initial events in the accelerated atherosclerotic process. The role of thrombin generated at the site of aortic injury in the subsequent neointimal proliferation was studied in rabbits (n = 16) 3 weeks after balloon catheter injury. In half of these animals, potent thrombin antagonists, r-hirudin and P-PACK, were administered to prevent acute thrombotic events. Compared to aortas with intact endothelium (n = 8), aortas de-endothelialised 21 days earlier showed neointimal hyperplasia as measured by the intimal/medial ratio (0.68 vs. 0.04, injured vs. normal aortas) and an increase in both total cholesterol (4.08 vs. 3.31 mg/g, p < 0.05) and lipid peroxide content (31.3 vs. 1.1 nmol/g; p < 0.001). Neointimal hyperplasia following endothelial denudation was inhibited in rabbits treated with thrombin-antagonists (0.27 vs. 0.68, treated vs. untreated, p = 0.012) and neither total cholesterol (3.48 mg/g) nor lipid peroxide content (1.5 nmol/g) differed significantly from that of intact arteries. By demonstrating a strong relationship between thrombin generation following de-endothelialisation and the progressive intimal proliferation, this study supports the hypothesis that thrombin is an important contributor to restenosis after vascular injury. The highly atherogenic lipid peroxidation seems to be linked to the early, thrombin-mediated events, as it was completely prevented by adequate thrombin antagonism.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsAntithrombinsAorta, ThoracicArteriosclerosisCatheterizationCholesterolEndothelium, VascularHyperplasiaLipid PeroxidationLipid PeroxidesMaleMicroscopy, Electron, Scanning

Резюме

Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process.

Почему это важно для гирудотерапии

This study examined the role of thrombin generation in neointimal proliferation and atherogenesis following balloon-catheter aortic injury in rabbits, administering thrombin antagonists (r-hirudin and P-PACK) to half the animals to prevent acute thrombotic events. Thrombin-antagonist treatment significantly inhibited neointimal hyperplasia (intimal/medial ratio 0.27 vs. 0.68, p = 0.012), and neither total cholesterol (3.48 mg/g) nor lipid peroxide content (1.5 nmol/g) in treated arteries differed significantly from intact arteries. The abstract refers to 'r-hirudin' without identifying it as leech-derived; its connection to ASH or hirudotherapy is inferable from general knowledge only. The study is an experimental animal model of an isolated recombinant molecule, not a clinical trial or live hirudotherapy evaluation.

Цитирование

Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process

Walters TK et al. · Journal of vascular research, 1994

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.